XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.3
Other (Income)/Deductions—Net - Footnotes (Detail)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
USD ($)
Sep. 29, 2024
USD ($)
facility
Mar. 31, 2024
USD ($)
Sep. 28, 2025
USD ($)
Sep. 29, 2024
USD ($)
facility
Loss Contingencies [Line Items]          
Net (gains) losses recognized during the period on equity securities [1] $ (201) $ (446)   $ 94 [2] $ (129) [2]
Net unrealized losses [3] 23 468   1,253 1,000
Intangible asset impairment charge       577  
Charge related to expected sale of facilities   $ 420     $ 420
Number of facilities for sale | facility   1     1
IPR&D [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charge [4],[5]       353  
IPR&D [Member] | Biopharma [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charge 260     260 $ 240
License [Member] | Biopharma [Member]          
Loss Contingencies [Line Items]          
Intangible asset impairment charge       210  
Haleon [Member]          
Loss Contingencies [Line Items]          
Net (gains) losses recognized during the period on equity securities       144  
Net unrealized losses       1,000  
Gain on sale of equity method investment     $ 150 900  
ViiV [Member]          
Loss Contingencies [Line Items]          
Dividend income   $ 48   $ 184 $ 183
ViiV [Member] | Biopharma [Member]          
Loss Contingencies [Line Items]          
Dividend income $ 72        
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The net losses in the first nine months of 2025 include, among other things, a net loss of $144 million related to our previous investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment in the first quarter of 2025.
[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of September 28, 2025, there were cumulative impairments and downward adjustments of $467 million and upward adjustments of $239 million. Impairments, downward and upward adjustments were not material to our operations in the third quarters and first nine months of 2025 and 2024.
[4] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
[5] See Note 9.